INO-1001

• CAT Number: I003291
• CAS Number: 3544-24-9
• Molecular Formula: C7H8N2O
• Molecular Weight: 136.2
• Purity: ≥95%
• Synonyms: 3-aminobenzamide
• Target: PARP
• Solubility: DMSO ≥25mg/mL Water <1 mg/mL Ethanol ≥25mg/mL
• Storage: room temp
• IC50: 3 nM
• InChI: InChI=1S/C7H8N2O/c8-6-3-1-2-5(4-6)7(9)10/h1-4H,8H2,(H2,9,10)
• InChIKey: GSCPDZHWVNUUFI-UHFFFAOYSA-N
• SMILES: C1=CC(=CC(=C1)N)C(=O)N

3-Aminobenzamide (Cat No.:I003291) is a potent inhibitor of Poly(ADP-ribose) polymerase (PARP). By blocking PARP activity, it interferes with the repair of damaged DNA and sensitizes cells to apoptosis. Additionally, 3-Aminobenzamide has shown potential in inhibiting secondary spinal cord injury (SCI) following spinal cord injury, exerting its effects in a caspase-independent manner. These findings suggest that 3-Aminobenzamide may have therapeutic implications for the treatment of SCI by modulating apoptosis pathways and reducing the extent of tissue damage.

Reference

[1]. Brock WA, et al. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 2004 Mar 18;205(2):155-60.
[2]. Roesner JP, Mersmann J, Bergt S, Bohnenberg K, Barthuber C, Szabo C, N?ldge-Schomburg GE, Zacharowski K.Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.Shock. 2010 May;33(5):507-12.
[3]. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P.A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.Cancer Invest. 2009 Aug;27(7):756-63.
[4]. Morrow DA, Brickman CM, Murphy SA, Baran K, Krakover R, Dauerman H, Kumar S, Slomowitz N, Grip L, McCabe CH, Salzman AL.A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial.J Thromb Thrombolysis. 2009 May;27(4):359-64. Epub 2008 Jun 6.
[5]. Mason KA, Valdecanas D, Hunter NR, Milas L.INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.Invest New Drugs. 2008 Feb;26(1):1-5. Epub 2007 Jul 13.